Nothing said here yet.
to join the conversation.
| Wang XiaodongDirector | Sell | 8,148 | $3.0M | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 6,903 | $2.5M | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 3,965 | $1.4M | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 2,841 | $1.0M | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 2,331 | $844.6K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 1,681 | $603.1K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 1,440 | $512.1K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 1,280 | $460.4K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 1,239 | $443.0K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 880 | $312.9K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 320 | $115.4K | Tue, Oct 27 |
| Wang XiaodongDirector | Sell | 10,361 | $3.6M | Tue, Oct 13 |
BeOne Medicines (ONC) is back in focus after fresh data at ESMO 2026. The update centered on TEVIMBRA plus ZIIHERA and chemotherapy in HER2-positive gastroesophageal cancer, where longer-term survival figures attracted renewed investor attention.
Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth.
Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth.
BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics.
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S.